Press release Biocartis NV

Biocartis Hosts Corporate Workshop and Announces Seven Idylla Abstracts to be Presented at AMP 2023 Annual Meeting - Seite 2

Roger Moody, Chief Executive Officer of Biocartis, commented: “Science and innovation are at the heart of our mission, and we are pleased that the MSKCC Clinical Pathology Team will present a case study on our products and discuss the impact that our products can make at our corporate workshop. Our commitment to advancing personalized medicine through cutting-edge diagnostics has led to not just one, but seven publications that showcase the performance and versatility of our Idylla technology.”

The Idylla abstracts selected for AMP 2023 can be downloaded here.

--- END ---

More information:

Investor Relations Biocartis
e-mail        [e-mail]

About Biocartis

With its revolutionary and proprietary Idylla Platform, Biocartis aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast and liver cancer, as well as for sepsis. More information: www.biocartis.com. Follow us on X (Twitter): @Biocartis_.

The Idylla Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, cleared for sales in the US and registered in many others countries. Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. November 2023, Biocartis NV. All rights reserved.

---

¹ For Research Use Only (RUO), not for use in diagnostic procedures. The Idylla BRAF Mutation Test is CE-IVD in Europe.
² Cleared in the US for detection of Lynch syndrome under K211181. The Idylla MSI Test is CE-IVD in Europe.
³ For Research Use Only (RUO), not for use in diagnostic procedures. The Idylla KRAS Mutation Test is CE-IVD in Europe.
⁴ For Research Use Only (RUO), not for use in diagnostic procedures.